Top

Published in:

01-03-2006 | Original Article

The Clinical Value of Parasternal Sentinel Node Biopsy in Breast Cancer

Authors: Marjut Hannele Kristiina Leidenius, MD, PhD, Leena Anneli Krogerus, MD, PhD, Terttu Sinikka Toivonen, MD, Esa Antero Leppänen, MD, PhD, Karl Albert Johan von Smitten, MD, PhD

Published in: Annals of Surgical Oncology | Issue 3/2006

Abstract

Background

Lymphoscintigraphy (LS) with sentinel node (SN) biopsy is proposed to provide a feasible method to complete lymphatic staging in breast cancer. The aim of this study was to evaluate the clinical value of parasternal SN biopsy.

Methods

A total of 984 consecutive patients with clinical stage T1/2N0 invasive breast cancer who underwent LS and SN biopsy were included in the study. A prospectively collected database was used. An intratumoral injection of 50 to 145 MBq of ^99mTc-labeled human albumin colloid (Nanocoll) was used for preoperative LS.

Results

LS showed the axillary SN in 844 (86%) cases and the parasternal SN in 138 (14%) cases. The median number of visualized parasternal SN was 2 (range, 1–6). Visualization of the parasternal SN was more common in patients with mediocentral tumors (81 of 399; 20%) and in patients with lateral tumors (56 of 585; 10%; P < .0001). Parasternal SNs were visualized more often, in 100 (17%) of 584 patients without axillary metastases compared with 38 (10%) of 400 patients with metastatic axillary nodes (P = .0006). Parasternal SNs were harvested successfully in 121 (88%) patients with visualization of those nodes. Parasternal SN metastases were detected in 18 patients, with a median of 1 metastasis (range, 1–4 metastases). Eight of these 18 patients were axillary node negative.

Conclusions

Parasternal SN biopsy results in upstaging in 2% of all breast cancer patients who undergo SN biopsy. The clinical value of the procedure seems insignificant, although it may influence the adjuvant treatment regimen in some patients.

Veronesi U, Cascinelli N, Greco M, et al. Prognosis of breast cancer patients after mastectomy and dissection of internal mammary nodes. Ann Surg 1985;202:702–7PubMed

Noguchi M, Ohta N, Kioyasaki N, Taniya T, Miyazaki I, Mizukami Y. Reappraisal of internal mammary node metastases as a prognostic factor in patients with breast cancer. Cancer 1991;68:1918–25PubMed

Arriagada R, Le ME. Adjuvant radiotherapy in breast cancer. The treatment of lymph node areas. Acta Oncol 2000;39:295–305PubMed

Freedman GM, Fowble BL, Nicolau N, et al. Should internal mammary lymph nodes in breast cancer be a target for the radiation oncologist? Int J Radiat Oncol Biol Phys 2000;46:805–14CrossRefPubMed

Estourgie SH, Tanis PJ, Nieweg OE, Valdes Olmos RA, Rutgers EJT, Kroon BBR. Should the hunt for internal mammary chain sentinel nodes begin? An evaluation of 150 breast cancer patients. Ann Surg Oncol 2004;10:935–41

Galimberti V, Veronesi P, Arnone P, et al. Stage migration after biopsy of internal mammary chain lymph nodes in breast cancer patients. Ann Surg Oncol 2002;9:924–8PubMed

Paganelli G, Galimberti V, Triforo G, et al. Internal mammary node lymphoscintigraphy and biopsy in breast cancer. Q J Nucl Med 2002;46:138–44PubMed

van der Ent FWC, Kengen RAM, van der Pol HAG, Povel JACM, Stroeken HJG, Hoofwijk AGM. Halstedt revisited: internal mammary sentinel lymph node biopsy in breast cancer. Ann Surg 2001;234:79–84PubMed

Dupont EL, Salud CJ, Peltz ES, et al. Clinical relevance of internal mammary node mapping as a guide to radiation therapy. Am J Surg 2001;182:321–4CrossRefPubMed

10.

Bevilaqua JLB, Gucciardo G, Cody HS III, et al. A selection algorithm for internal mammary sentinel lymph node biopsy in breast cancer. Eur J Surg Oncol 2002;28:603–14

11.

Benda RK, Cendan JC, Copeland EM, et al. Should decisions on internal mammary lymph node irradiation be based on current lymphoscintigraphy techniques for sentinel lymph node identification? Cancer 2004;100:518–23CrossRefPubMed

12.

Fabry HJ, Mutsaers PGNJ, Meijer S, et al. Clinical relevance of parasternal uptake in sentinel node procedure for breast cancer. J Surg Oncol 2004;87:13–8CrossRefPubMed

13.

Leidenius MH, von Smitten KA, Hietanen PS. Patient preference for dissection of sentinel nodes outside level I-II of the axilla. Acta Oncol 2002;41:652–8PubMed

14.

Sacchini V, Borgen P, Galimberti V, et al. Surgical approach to internal mammary lymph node biopsy. J Am Coll Surg 2001;193:709–13CrossRefPubMed

15.

Sobin LH, Wittekind C (eds). UICC TNM Classification of Malignant Tumours. 6th ed. New York: Wiley, 2002

16.

Leppänen E, Leidenius M, Krogerus L, von Smitten K. The effect of patient and tumour related characteristics on visualisation of sentinel nodes after a single intratumoural injection of Tc 99m labelled human albumin colloid in breast cancer. Eur J Surg Oncol 2002;28:821–6PubMed

17.

Shimazu K, Tamaki Y, Taguchi T, et al. Lymphoscintigraphic visualization of internal mammary nodes with subtumoral injection of radiocolloid in patients with breast cancer. Ann Surg 2003;237:390–8CrossRefPubMed

18.

Krynyckyi BR, Chun H, Kim HH, Eskandar Y, Kim CK, Machac J. Factors affecting visualization rates of internal mammary sentinel nodes during lymphoscintigraphy. J Nucl Med 2003;44:1387–93PubMed

19.

Uren RF, Howman-Giles R, Renwick SB, Gillet D. Lymphatic mapping of the breast: locating the sentinel lymph nodes. World J Surg 2001;25:789–93CrossRefPubMed

20.

Morrow M, Foster RS. Staging of breast cancer. A new rationale for internal mammary node biopsy. Arch Surg 1981;166:748–51

21.

Donegan WL. The influence of untreated internal mammary metastases upon the course of mammary cancer. Cancer 1977;39:533–8PubMed

22.

Lacour J, Le M, Caceres E, Koszarowski T, Veronesi U, Hill C. Radical mastectomy versus radical mastectomy plus internal mammary dissection. Cancer 1983;51:1941–3PubMed

23.

Rönkä R, Krogerus L, Leppänen E, von Smitten K, Leidenius M. Sentinel nodes outside level I-II of the axilla and staging in breast cancer. Anticancer Res 2002;22:3109–12PubMed

24.

Miltenburg DM, Miller C, Karamlou TB, Brunicardi FC. Meta-analysis of sentinel lymph node biopsy in breast cancer. J Surg Res 1999;84:138–42CrossRefPubMed

25.

Wong SL, Edwards MJ, Chao C, Simpson D, McMasters KM. The effect of lymphatic tumour burden on sentinel lymph node biopsy results. Breast J 2002;8:192–8CrossRefPubMed

Title: The Clinical Value of Parasternal Sentinel Node Biopsy in Breast Cancer
Authors: Marjut Hannele Kristiina Leidenius, MD, PhD
Leena Anneli Krogerus, MD, PhD
Terttu Sinikka Toivonen, MD
Esa Antero Leppänen, MD, PhD
Karl Albert Johan von Smitten, MD, PhD
Publication date: 01-03-2006
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 3/2006
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/ASO.2006.02.022

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Clinical Value of Parasternal Sentinel Node Biopsy in Breast Cancer

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2006

The Growing Pains of Neoadjuvant Trials for Gastroesophageal Carcinoma

Improved Staging With Pretreatment Positron Emission Tomography/Computed Tomography in Low Rectal Cancer

Can Rectal Cancers With Pathologic T0 After Neoadjuvant Chemoradiation (ypT0) Be Treated by Transanal Excision Alone?

Surgery in the Era of Gene Expression Profiling–Based Prediction and Individualized, Neoadjuvant Breast Cancer Therapy: The Beginning of the End?

Chemotherapy and Radiotherapy in the Treatment of Resectable Non–Small-Cell Lung Cancer

Effect of Obesity on Presentation of Breast Cancer